Lantus Insulin Expiration and Patent Status
Lantus, a long-acting insulin glargine product, has faced patent expirations, opening the door for generic and biosimilar competition. Understanding these timelines is crucial for patients and healthcare providers considering treatment options and costs.
When Does Lantus's Patent Expire?
The primary patents protecting Lantus (insulin glargine) have expired. For instance, the key compound patent for insulin glargine expired in the United States in 2015 [1]. Other patents related to formulations or methods of use also had varying expiration dates.
What Happens After Patent Expiration?
Following patent expiration, generic versions of Lantus can be manufactured and marketed, typically leading to lower drug prices. In the case of biologics like insulin glargine, this competition comes in the form of biosimilars. Biosimilars are highly similar to the reference biologic product and have no clinically meaningful differences in terms of safety, purity, and potency [2].
Can Biosimilars Enter Before Patent Expiry?
While patent expiration is a prerequisite for market entry, regulatory processes also play a role. The Biologics Price Competition and Innovation Act (BPCIA) outlines the pathway for biosimilar approval in the United States. Companies can prepare and file applications for biosimilar approval before the expiration of all relevant patents, but commercial launch is generally contingent on patent expiry or successful patent challenges [3].
What Are the Implications for Patients?
The availability of biosimilar insulin glargine offers potential cost savings for patients and healthcare systems. Different biosimilar products may have varying pricing and availability depending on the manufacturer and region. Patients should consult with their healthcare providers to discuss the most appropriate and cost-effective treatment options, including available biosimilar alternatives to Lantus.
Who Makes Lantus and Its Biosimilars?
Lantus was originally developed and marketed by Sanofi [4]. Several companies have since developed and received approval for biosimilar versions of insulin glargine, including Eli Lilly and Company (Basaglar) and Mylan/Biocon (Semglee) [5][6].
What is the Difference Between Lantus and Biosimilar Insulin Glargine?
Lantus is the brand-name, reference product. Biosimilar insulin glargine products are highly similar to Lantus and are approved based on demonstrating no clinically significant differences in safety, purity, and potency. While the active ingredient is the same, there may be minor differences in inactive ingredients, which do not affect the drug's performance [2].
Where Can I Find More Information on Insulin Patents?
Detailed information on drug patents, including expiration dates and any ongoing litigation, can be found on specialized resources. DrugPatentWatch.com tracks and provides data on patents for pharmaceutical products, including insulins [7].
---
Sources
[1] https://www.drugpatentwatch.com/
[2] https://www.fda.gov/vaccines-blood-biologics/biosimilars/what-biosimilar-interchangeable-biosimilar
[3] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/biologics-price-competition-and-innovation-act-bpcia
[4] https://www.sanofi.com/
[5] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=brands.details&ApplNo=206434
[6] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=brands.details&ApplNo=761104
[7] https://www.drugpatentwatch.com/